Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Biosyent Inc V.RX

Alternate Symbol(s):  BIOYF

BioSyent Inc. is a specialty pharmaceutical company. The Company, through its wholly owned subsidiaries, BioSyent Pharma Inc., and BioSyent Pharma International Inc., acquires or licenses and develops pharmaceutical and other healthcare products for sale in Canada and certain international markets. Hedley Technologies Ltd., a wholly owned subsidiary operates the Company’s business marketing biologically and health friendly non-chemical insecticides. Its products include Combogesic, Cathejell, FeraMAX Pd Therapeutic 150, FeraMAX Pd Maintenance 45, FeraMAX Pd Powder 15, Gelclair, Inofolic, Proktis-M, RepaGyn, and Tibella. Combogesic is for the short-term management of mild to moderate acute pain and the reduction of fever in adults. Cathejell combines sterile gel and 2% lidocaine jelly in a collapsible syringe that is ready to use. FeraMAX Pd Therapeutic 150 is an oral hematinic that helps the body form red blood cells and is indicated for the treatment of iron deficiency anemia.


TSXV:RX - Post by User

Bullboard Posts
Comment by kingposton Aug 04, 2014 8:39pm
182 Views
Post# 22808319

RE:RE:Todays Close $7.56 DOWN 39 cents (- 4.55%)

RE:RE:Todays Close $7.56 DOWN 39 cents (- 4.55%)agree with your comments sportsguy ..... just curious how much conviction do you have with pdp .... I like it as well and also have a position there, but consider it a bit more speculative than rx... I consider RX's business model as near perfect....pdp is very similar in business model but currently anyway, focuses on the child medical products --pediatrics... it may prove to be an excellent niche... RX has virtually no competition in the products they are targeting, currently, and they do not rely on the tax inversion potential like the bigger companies in this sector....GUD, MSL Cipher, Concordia , Valient etc.... PDP could surprise some people though I like how they only need 20 sales persons (which they already have) to target the whole pediatric community,  and so very focused and niche, ... I can actually see it as possible that for some drugs they might give pdp the child market and RX the adult market..Another scenario is where a big drug co has not the time to do the work on the much smaller child market and pdp can offer to run the approval and marketing of this nich, with little affect to the adult market that is being run seperately.....All in all RX and PDP both look very attractive long term...
Bullboard Posts